Celularity (CELU) EBIT Margin (2020 - 2026)
Celularity (CELU) recorded EBIT Margin of -537.48% in Q4 2025, down 486.30 percentage points from -51.18% a year earlier and down 293.34 percentage points from the prior quarter.
Celularity (CELU) EBIT Margin (2020 - 2026) Analysis & Trends
For FY2025, Celularity reported EBIT Margin of -230.92%, down 160.17 percentage points from FY2024.
- Annual EBIT Margin has a five-year change of +833.13 percentage points (FY2020 to FY2025).
- Across earlier years, EBIT Margin came in at -70.75% in FY2024 (+773.69 pp), -844.44% in FY2023 (-702.02 pp), -142.42% in FY2022 (+368.75 pp) and -511.17% in FY2021 (+552.88 pp).
- The Q4 2025 figure is the lowest quarterly EBIT Margin since Q3 2023.
- On a year-over-year basis, EBIT Margin has declined for five consecutive quarters, with an average year-over-year change of +553.83 percentage points over the last eight quarters.
- Peak year-over-year performance for EBIT Margin in the last five years was a gain of 2497.66 percentage points in Q3 2024, against a drop of 2485.12 percentage points in Q3 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at -244.13% (Q3 2025), -276.57% (Q2 2025) and -91.77% (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 37.40% |
| 10 | Celularity | 39.39 Mn | 31.87 Mn | 2.39 Mn | -263.47% |
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -263.47% |
| Dec 31, 2025 | -537.48% |
| Sep 30, 2025 | -244.13% |
| Jun 30, 2025 | -276.57% |
| Mar 31, 2025 | -91.77% |
| Dec 31, 2024 | -51.18% |
| Sep 30, 2024 | -124.00% |
| Jun 30, 2024 | -84.01% |
| Mar 31, 2024 | -50.24% |
| Dec 31, 2023 | 109.93% |
| Sep 30, 2023 | -2,621.66% |
| Jun 30, 2023 | -1,445.75% |
| Mar 31, 2023 | -1,623.13% |
| Dec 31, 2022 | 423.47% |
| Sep 30, 2022 | -136.54% |
| Jun 30, 2022 | 110.57% |
| Mar 31, 2022 | -701.16% |
| Dec 31, 2021 | -307.89% |
| Sep 30, 2021 | 102.60% |
| Jun 30, 2021 | -1,895.87% |
Celularity EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=CELU&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "CELU", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=CELU&period=max&api_key=YOUR_API_KEY");
const data = await res.json();